ReviewViruses2024
HIV-TB Coinfection: Current Therapeutic Approaches and Drug Interactions.
Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis.Journal of the International Association of Providers of AIDS CarePooled it
- Hypercalcemia in a Patient With Spinal Tuberculosis and Aspergillus Co-Infection: A Case-Report.Immunity, inflammation and disease · 2026Article
- Liposomal Glutathione Exhibits Direct and Intracellular Antimycobacterial Activity AgainstBioengineering (Basel, Switzerland) · 2026Article
- Tuberculosis (TB) service utilisation pre and peri-COVID-19 restrictions in Johannesburg, Gauteng.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026Article
- The Impact of HIV Viral Suppression and Immune Status on Rifampicin-Resistant Tuberculosis Outcomes: A Systematic Review and Meta-Analysis Protocol.Tropical medicine and infectious disease · 2026Review
- Prevalence and Risk Factors of Latent Tuberculosis Infection among People Living with HIV in Mongolia.Infection & chemotherapy · 2026Article
- Water-Soluble Inclusion Complexation of Naphthyl-Containing Thiosemicarbazides and Thioureas with β-Cyclodextrin.Molecules (Basel, Switzerland) · 2026Article
- Bedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends.Antibiotics (Basel, Switzerland) · 2026Review
- Barriers to treatment completion among drug-sensitive tuberculosis patients: evidence from Indonesia's tuberculosis surveillance system.Osong public health and research perspectives · 2026Article
- Diagnostic value of miR-155, miR-29a and lncRNAs (NEAT1, GAS5 and COX2) in HIV, tuberculosis, and HIV/TB co-infection.Scientific reports · 2026Article
- Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil.Memorias do Instituto Oswaldo Cruz · 2026Observational
- Determinants of tuberculosis presentation and successful treatment outcome among tuberculosis patients in Geita, Tanzania.PloS one · 2026Article
- Proposing Bromo-Epi-Androsterone for Host-Directed Therapy Against Tuberculosis.Pathogens (Basel, Switzerland) · 2025Review
- Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance.Pharmaceutics · 2025Review
- High prevalence of co-infections with latent tuberculosis, syphilis and hepatitis B and C among people with HIV in Ghana: a call for integrating screening into routine care.AIDS research and therapy · 2025Article
- Nutritional Deficiencies and Management in Tuberculosis: Pharmacotherapeutic and Clinical Implications.Nutrients · 2025Review
- Host-Directed Therapies Based on Protease Inhibitors to ControlMicroorganisms · 2025Review
- Metabolic Reprogramming in HIV+ CD4Metabolites · 2025Article
- PBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability.The AAPS journal · 2025Article
- Predicting treatment adherence in patients with drug-resistant tuberculosis: insights from socioeconomic, demographic, and clinical factors of patients in the rural Eastern Cape.Frontiers in tuberculosis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The co-occurrence of human immunodeficiency virus (HIV) and tuberculosis (TB) infection poses a significant global health challenge. Treatment of HIV and TB co-infection often necessitates combination therapy involving antiretroviral therapy (ART) for HIV and anti-TB medications, which introduces the potential for drug-drug interactions (DDIs). These interactions can significantly impact treatment outcomes, the efficacy of treatment, safety, and overall patient well-being. This review aims to provide a comprehensive analysis of the DDIs between anti-HIV and anti-TB drugs as well as potential adverse effects resulting from the concomitant use of these medications. Furthermore, such findings may be used to develop personalized therapeutic strategies, dose adjustments, or alternative drug choices to minimize the risk of adverse outcomes and ensure the effective management of HIV and TB co-infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.